Valneva SE (VALN) EBT (2021 - 2026)
Valneva SE (VALN) posted EBT of -$36.6 million for Q1 2026, up 38.47% sequentially from -$59.5 million in Q4 2025, and down 348.31% YoY from $14.7 million in Q1 2025.
Valneva SE (VALN) EBT (2021 - 2026) Analysis & Trends
Valneva SE has reported EBT for 6 years, with the latest figure at -$36.6 million in Q1 2026.
- Quarterly EBT fell 348.31% year-over-year to -$36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160.2 million (down 90.79% YoY) and the FY2025 annual result came in at -$132.8 million, down 968.55% from the prior year.
- EBT rose to -$36.6 million in Q1 2026 per VALN's latest filing, from -$59.5 million in the prior quarter.
- Over five years, EBT peaked at $72.9 million in Q3 2022 and troughed at -$153.3 million in Q2 2022.
- A 5-year average of -$26.2 million and a median of -$28.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2024 and 2026: EBT surged 426.81% in 2024, then plunged 348.31% in 2026.
- Over 5 years, EBT stood at -$48.9 million in 2022, then soared by 37.8% to -$30.4 million in 2023, then dropped by 13.7% to -$34.6 million in 2024, then tumbled by 72.01% to -$59.5 million in 2025, then jumped by 38.47% to -$36.6 million in 2026.
- According to Business Quant data, EBT over the past three periods registered -$36.6 million, -$59.5 million, and -$50.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | -36.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.93 Mn |
| Mar 31, 2026 | -36.58 Mn |
| Dec 31, 2025 | -59.46 Mn |
| Sep 30, 2025 | -50.82 Mn |
| Jun 30, 2025 | -13.37 Mn |
| Mar 31, 2025 | -8.16 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -14.23 Mn |
| Jun 30, 2024 | -27.03 Mn |
| Mar 31, 2024 | 64.01 Mn |
| Dec 31, 2023 | -30.40 Mn |
| Sep 30, 2023 | -34.35 Mn |
| Jun 30, 2023 | -22.41 Mn |
| Mar 31, 2023 | -19.59 Mn |
| Dec 31, 2022 | -48.87 Mn |
| Sep 30, 2022 | 72.91 Mn |
| Jun 30, 2022 | -153.32 Mn |
| Mar 31, 2022 | -28.66 Mn |
| Dec 31, 2021 | 199.40 Mn |
| Sep 30, 2021 | -186.98 Mn |